Table 1

Demographic and clinical disease activity characteristics of patients with PsA

Mean (SD) age, years56.5 (13.2)
BMI, median (IQR)27 (25–30.5)
Disease duration, median (IQR), years10 (3–17)
Axial involvement, n (%)21 (17.7)
Tender joints, median (IQR)2 (0–4)
Swollen joints, median (IQR)1 (0–1)
BSA, % (IQR)2 (0–4)
Enthesitis (LEI), median (IQR)0 (0–1)
CRP, median (IQR), mg/dL0.4 (0.2–0.6)
MDA 5/7, n (%)57 (48.3)
DAPSA, median (IQR)9.3 (4–16.2)
HAQ-DI, median (IQR)0.25 (0.125–0.5)
PsAID (IQR)2.2 (1–4.2)
VAS pain, median (IQR), cm4 (1–6)
PtGA, median (IQR), cm3 (1.5–6)
PASS yes/no80/38
Treatment, n (%)
 csDMARD monotherapy33 (27.9)
 Etanercept20 (16.9)
 Adalimumab19 (16.2)
 Golimumab6 (5)
 Ustekinumab16 (13.6)
 Secukinumab16 (13.6)
 Ixekizumab5 (4.3)
 Apremilast3 (2.5)
  • BMI, body mass index; CRP, C reactive protein; csDMARD, conventional synthetic disease-modifying antirheumatic drugs; DAPSA, Disease Activity Score for Psoriatic Arthritis; HAQ-DI, Health Assessment Questionnaire-Disability Index; MDA, minimal disease activity; PASS, Patient Acceptable Symptom State; PsA, psoriatic arthritis; PsAID, Psoriatic Arthritis Impact of Disease; PtGA, Patient Global Assessment; VAS, Visual Analogue Scale.